VVVivek Verma

Vivek Verma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vivek Verma has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Formulation and evaluation sustained and immediate release bilayer tablet of telmisartan and amlodipine

    by Prashant Kumar, Vivek Verma, Mujahidul Islam

    The study was undertaken with the aim to Formulation and evaluation of bilayer tablet formulation of Telmisartan and Amlodipine. Thus, from the results, it is concluded that the formulation of immediate release layer of Amlodipine using 4-2% concentration of Crospovidone & PVA K30 and 30-20-1.5% concentration of HPMC K 100M-HPMC K4 M-HPMC K15 M are considered as ideal for optimized bilayer tablet formulation. The drug release data of the Telmisartan and Amlodipine was fitted into various kinetic models which as shown in figures 3.8 and 3.11. The order of release of drug was found to be zero order, in which R2 value was close to 1. The n value of Korsmeyer Peppas equation was found to be 0.746. Good correlation coefficients are obtained for Higuchi equation. The results showed that the formulation followed Peppas Model release. Thus, this optimized bilayer tablet formulation can be successfully used in the treatment of hypertension. This modified release bilayer tablets also reduced dosing frequency, increase the bioavailability and provide better patient compliance. From the results it was found that formulation F4 was the best formulation amongst the 5 formulations.


  • Open Access

    Investigating the Feasibility of Mefenamic Acid Nanosuspension for Pediatric Delivery: Preparation, Characterization, and Role of Excipients

    by Nikhat Perween, Sultan Alshehri, T. S. Easwari, Vivek Verma, Faiyazuddin, Abdullah Alanazi, Faiyaz Shakeel

    Molecules with poor aqueous solubility are difficult to formulate using conventional approaches and are associated with many formulation delivery issues. To overcome these obstacles, nanosuspension technology can be one of the promising approaches. Hence, in this study, the feasibility of mefenamic acid (MA) oral nanosuspension was investigated for pediatric delivery by studying the role of excipients and optimizing the techniques. Nanosuspensions of MA were prepared by adopting an antisolvent precipitation method, followed by ultrasonication with varying concentrations of polymers, surfactants, and microfluidics. The prepared nanosuspensions were evaluated for particle size, morphology, and rheological measures. Hydroxypropyl methylcellulose (HPMC) with varying concentrations and different stabilizers including Tween® 80 and sodium dodecyl sulfate (SLS) were used to restrain the particle size growth of the developed nanosuspension. The optimized nanosuspension formula was stable for more than 3 weeks and showed a reduced particle size of 510 nm with a polydispersity index of 0.329. It was observed that the type and ratio of polymer stabilizers were responsive on the particle contour and dimension and stability. We have developed a biologically compatible oral nanoformulation for a first-in-class drug beautifully designed for pediatric delivery that will be progressed toward further in vivo enabling studies. Finally, the nanosuspension could be considered a promising carrier for pediatric delivery of MA through the oral route with enhanced biological impact.